These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 36996853)
21. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273 [TBL] [Abstract][Full Text] [Related]
22. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. Iversen J; Wand H; McManus H; Dore GJ; Maher L Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842 [TBL] [Abstract][Full Text] [Related]
23. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R; BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474 [TBL] [Abstract][Full Text] [Related]
25. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada. Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888 [TBL] [Abstract][Full Text] [Related]
26. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ; Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135 [TBL] [Abstract][Full Text] [Related]
27. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study. Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626 [TBL] [Abstract][Full Text] [Related]
28. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477 [TBL] [Abstract][Full Text] [Related]
29. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533 [TBL] [Abstract][Full Text] [Related]
30. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):39-56. PubMed ID: 33217341 [TBL] [Abstract][Full Text] [Related]
31. Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis. Syangbo A; Hickman M; Colledge-Frisby S; Leung J; Grebely J; Larney S; Degenhardt L; Trickey A Drug Alcohol Rev; 2023 Mar; 42(3):569-581. PubMed ID: 36600489 [TBL] [Abstract][Full Text] [Related]
32. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802 [TBL] [Abstract][Full Text] [Related]
34. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB; J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684 [TBL] [Abstract][Full Text] [Related]
35. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Smit C; Boyd A; Rijnders BJA; van de Laar TJW; Leyten EM; Bierman WF; Brinkman K; Claassen MAA; den Hollander J; Boerekamps A; Newsum AM; Schinkel J; Prins M; Arends JE; Op de Coul ELM; van der Valk M; Reiss P; Lancet HIV; 2021 Feb; 8(2):e96-e105. PubMed ID: 33357835 [TBL] [Abstract][Full Text] [Related]
36. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. Lansky A; Finlayson T; Johnson C; Holtzman D; Wejnert C; Mitsch A; Gust D; Chen R; Mizuno Y; Crepaz N PLoS One; 2014; 9(5):e97596. PubMed ID: 24840662 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. Aghaei AM; Gholami J; Sangchooli A; Rostam-Abadi Y; Olamazadeh S; Ardeshir M; Baheshmat S; Shadloo B; Taj M; Saeed K; Rahimi-Movaghar A Lancet Glob Health; 2023 Aug; 11(8):e1225-e1237. PubMed ID: 37474230 [TBL] [Abstract][Full Text] [Related]
38. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. Mumtaz GR; Weiss HA; Thomas SL; Riome S; Setayesh H; Riedner G; Semini I; Tawil O; Akala FA; Wilson D; Abu-Raddad LJ PLoS Med; 2014 Jun; 11(6):e1001663. PubMed ID: 24937136 [TBL] [Abstract][Full Text] [Related]
39. A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators? Leung J; Peacock A; Colledge S; Grebely J; Cunningham EB; Hickman M; Vickerman P; Stone J; Trickey A; Dumchev K; Lynskey M; Hines L; Griffiths P; Mattick RP; Degenhardt L; Larney S J Infect Dis; 2019 Jun; 220(1):78-90. PubMed ID: 30726973 [TBL] [Abstract][Full Text] [Related]
40. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis. Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]